DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study

Introduction Vedolizumab (VDZ), a gut-selective humanised monoclonal antibody that targets α4β7 integrin, is approved for moderately to severely active Crohn’s disease and ulcerative colitis (UC). The ongoing GEMINI open-label extension (OLE) trial is investigating the long-term safety of VDZ (NCT00790933). We report 5 year exploratory interim analyses of effectiveness and safety in patients (pts) with UC who completed GEMINI 1 and enrolled in GEMINI OLE. Method Pts who responded to VDZ induction at Week (Wk) 6 received VDZ maintenance (every 8 or 4wks) to Wk 52 of GEMINI 1 and VDZ every 4 wks in GEMINI OLE. In an interim analysis, pts with 248 wks of cumulative VDZ (22 May 2009 to 21 May 2015) were assessed for clinical response (decrease in partial Mayo Score [PMS] of 2 points and 25% change from baseline [BL], with an accompanying decrease in rectal bleeding subscore of 1 point from BL or absolute rectal bleeding subscore of 1 point), clinical remission (PMS of 2 with no individual subscore >1), health-related quality of life (HRQoL) and safety. Results Of 154 pts (anti-tumour necrosis factor-alpha: naive n=107, failure n=42), 63 had 248 wks’ cumulative VDZ treatment, 54 discontinued (n=19 [35%] due to lack of continued benefit) and a further 37 (24%) had not yet reached 248 wks at data cut-off. Of pts with Wk 248 data, 98% had clinical response and 90% were in remission. HRQoL was improved at Wk 248, with mean change from BL in the Inflammatory Bowel Disease Questionnaire and Euro Quality of Life-5D visual analogue scale scores of 58.7 and 24.0, respectively. At Wk 248, 142 pts had adverse events (AEs), of which 16 discontinued and 46 experienced a serious AE (drug-related n=7; 8 pts discontinued; no deaths). Abstract AODWE-002 Table 1 Effectiveness of long-term VDZ in pts with UC Conclusion Continued clinical response, remission and HRQoL improvements were observed throughout 248 wks (~5 years) of cumulative VDZ therapy in pts with UC who responded at Wk 6, completed GEMINI 1 and enrolled in the OLE. The long-term safety profile of VDZ was consistent with that reported in previous studies. Disclosure of Interest A Kaser Conflict with: Boehringer Ingelheim, Eisai, Ferring, Genentech, GlaxoSmithKline, Hospira, Janssen J and J, Kymab, Second Genome, Shire, VHsquared, Conflict with: Lecture fee(s): Falk, Ferring, Takeda; serves as course director of the Cambridge – MedImmune PhD programme